Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 25;22(3):1170.
doi: 10.3390/ijms22031170.

Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy

Arunbalaji Pugazhendhi  1 , Margaret Hubbell  1 , Pooja Jairam  2 , Balamurali Ambati  1
Affiliations
Review

Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy

Arunbalaji Pugazhendhi et al. Int J Mol Sci. .

Abstract

Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population causing gradual vision impairment. Risk factors such as age, race, genetics, iris color, smoking, drinking, BMI, and diet all play a part in nvAMD's progression, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the mainstay of treatment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies such as gene therapies, Rho-kinase inhibitors, and levodopa offer potential new targets for treatment.

Keywords: age-related macular degeneration; anti-VEGF; etiopathogenesis; future advancements; gene-therapy; neovascular age-related macular degeneration; risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of AMD pathogenesis.
Figure 2
Figure 2
Progression of AMD.
Figure 3
Figure 3
NLRP3 inflammasome [116].
Figure 4
Figure 4
Mechanism of anti-VEGF drugs.
See this image and copyright information in PMC

References

    1. Wong W.L., Su X., Li X., Cheung C.M., Klein R., Cheng C.Y., Wong T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health. 2014;2:e106–e116. doi: 10.1016/S2214-109X(13)70145-1. - DOI - PubMed
    1. Chapman N.A., Jacobs R.J., Braakhuis A.J. Role of diet and food intake in age-related macular degeneration: A systematic review. Clin. Exp. Ophthalmol. 2019;47:106–127. doi: 10.1111/ceo.13343. - DOI - PubMed
    1. Kokotas H., Grigoriadou M., Petersen M.B. Age-related macular degeneration: Genetic and clinical findings. Clin. Chem. Lab. Med. 2011;49:601–616. doi: 10.1515/CCLM.2011.091. - DOI - PubMed
    1. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 2001;119:1417–1436. doi: 10.1001/archopht.119.10.1417. - DOI - PMC - PubMed
    1. Age-Related Eye Disease Study Research Group Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000;107:2224–2232. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources